IRIS
VANNI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.359
AS - Asia 27
NA - Nord America 3
SA - Sud America 3
Totale 4.392
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.359
CN - Cina 23
BR - Brasile 3
SG - Singapore 3
US - Stati Uniti d'America 3
UZ - Uzbekistan 1
Totale 4.392
Salva come PNG Salva come JPEG
Città #
Genova 1.905
Genoa 1.540
Rapallo 524
Vado Ligure 380
Bordighera 10
Beijing 8
Ashburn 3
Singapore 2
Araraquara 1
Bukhara 1
Guarapari 1
Serra 1
Totale 4.376
Salva come PNG Salva come JPEG
Nome #
Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients 179
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 169
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 156
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 151
Belagenpumatucel-L for the treatment of non-small cell lung cancer 142
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 140
Oral vinorelbine in the treatment of non-small-cell lung cancer. 131
Coping with formalin banning in pathology: under vacuum long-term tissue storage with no added formalin 123
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 121
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients 117
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors 117
Molecular characterization of hospital-acquired methicillin-resistant Staphylococcus aureus strains in pediatric outbreaks using variable tandem repeat analysis with spa and ClfB typing. 115
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 110
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 108
Human leukocyte antigen-B (-Bw6/-Bw4 I 80, T 80) and human leukocyte antigen-C (-C1/-C2) subgrouping using pyrosequence analysis 108
Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM™ platform 106
An improved method for HLA-B and -C supratyping 106
Current State of Target Treatment in BRAF Mutated Melanoma 105
Exosomes: a new horizon in lung cancer 103
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 99
Understanding the checkpoint blockade in lung cancer immunotherapy 99
Afatinib for the treatment of non-small cell lung cancer 96
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 96
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 96
Whole-genome sequencing as standard practice for the analysis of clonality in outbreaks of meticillin-resistant Staphylococcus aureus in a paediatric setting 90
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 87
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 87
Vinflunine for the treatment of non-small cell lung cancer 85
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: Report of a secondary anaplastic astrocytoma carrying the IDH1 mutation 84
Development and validation of a multiplex quantitative polymerase chain reaction assay for the detection of Mollicutes impurities in human cells, cultured under good manufacturing practice conditions, and following European Pharmacopoeia requirements and the International Conference on Harmonization guidelines 78
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer 77
Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients 73
Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma 71
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 67
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 67
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma 67
A sensible technique to detect mollicutes impurities in human cells cultured in GMP condition 64
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples 62
Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments 62
A NEXT GENERATION SEQUENCING APPROACH TO GENOMIC LANDSCAPE IN MELANOMA PATIENTS: EVOLUTION OF PATIENT-SPECIFIC RESPONSE TO THERAPY 61
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 56
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 56
Molecular Assessment in Patients with Melanoma: When and Why? 55
Troubleshooting fine-tuning procedures for qPCR system design 55
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy” 51
Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms 51
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 45
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report 39
Germline POT1 Variants: A Critical Perspective on POT1 Tumor Predisposition Syndrome 34
Totale 4.517
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.438
article - articoli 19.907
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 276
Totale 40.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021770 0 0 0 208 26 32 223 60 75 58 54 34
2021/2022522 66 11 17 39 23 33 11 133 17 66 16 90
2022/2023605 51 57 8 49 100 99 2 42 100 8 87 2
2023/2024335 8 40 14 42 22 49 11 38 18 15 8 70
2024/20251.049 25 63 34 57 142 91 142 182 61 59 96 97
2025/2026518 257 31 131 99 0 0 0 0 0 0 0 0
Totale 4.517